TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28538380
Drug: Cinacalcet (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet (30 mg)
Study: 21879181
Drug: Rectal ozone
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal ozone therapy
Study: 21879181
Drug: Rectal medicinal
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal medicinal oxygen
Study: 11503783
Drug: Cisplatin (monotherapy)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (monotherapy)
Study: 8384187
Drug: ECA (ephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECA (ephedrine 75‐150mg, caffeine 150mg, aspirin 330mg)
Study: 3519551
Drug: Once-a-week radiation
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Once-a-week radiation therapy (1 X W) - 6000 rad using 500 rad fractions for 12 weeks
Study: 3519551
Drug: Daily radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily radiation therapy (5 X W) - 6000 rad using 200 rad fractions for 6 weeks
Study: 30885221
Drug: Armolipid Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armolipid Plus (AP) - 500 mg berberine, 3 mg monacolin K, 10 mg policosanol, once daily for 24 weeks
Study: 30885221
Drug: Placebo (PL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PL) - once daily for 24 weeks
Study: 25161155
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg empagliflozin with 40 mg simvastatin
Study: 14607714
Drug: Electro-acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture therapy (EAT) in combination with liver artery intubation chemotherapy (Group A)
Study: 14607714
Drug: Electro-acupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-acupuncture therapy (EAT) alone (Group B)
Study: 14607714
Drug: Liver artery
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver artery intubation chemotherapy alone (Group C)
Study: 7744151
Drug: Pyridoxine administration
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine administration
Study: 2282207
Drug: Magnesium supplement
Normalized name: Magnesium supplement
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium supplement
Study: 6786067
Drug: diltiazem (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem (120 mg/day)
Study: 6786067
Drug: diltiazem (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem (240 mg/day)
Study: 30626095
Drug: 4-day protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-day protein restricted diet (0.25 g protein/kg body weight/day)
Study: 30626095
Drug: Habitual diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habitual diet (1.3 ± 0.3 g protein/kg body weight/day)
Study: 25391549
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone ER tablet with low-level coating
Study: 25391549
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone ER tablet with intermediate-level coating
Study: 25391549
Drug: Hydrocodone ER
Normalized name: hydrocodone Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone ER tablet with high-level coating
Study: 25391549
Drug: Hydrocodone IR/acetaminophen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocodone IR/acetaminophen (APAP) 10/325 mg
Study: 23832726
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist group (Group A) - r‐FSH (50‐75 IU/d) plus cetrorelix (0.25 mg/d) starting when ≥ 2 follicles ≥ 14 mm were detected on ultrasound scan.
Study: 23832726
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist group (Group A)
Study: 20942865
Drug: MPT (melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPT (melphalan 9 mg/m²/d for 4 days every 6 weeks, prednisone 60 mg/m²/d for 4 days every 6 weeks, thalidomide 100 mg/d continuously)
Study: 20942865
Drug: MP (melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP (melphalan 9 mg/m²/d for 4 days every 6 weeks, prednisone 60 mg/m²/d for 4 days every 6 weeks)
Study: 19604191
Drug: Oral triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral triiodothyronine (T(3)) replacement therapy, 20 microg every 12 h starting just before induction of anaesthesia until the first day after surgery
Study: 19604191
Drug: Oral triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral triiodothyronine (T(3)) replacement therapy
Study: 16262513
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for delinquency and alcohol and/or marijuana use disorders
Study: 7483800
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine containing the Urabe mumps strain
Study: 7483800
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine containing the Jeryl Lynn mumps strain
Study: 7483800
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine containing the Schwarz strain
Study: 7483800
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine (all types)
Study: 30541641
Drug: Volume Controlled
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volume Controlled Ventilation (VCV) with 7 L/min atomized oxygen flow
Study: 30541641
Drug: Pressure Controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressure Controlled Ventilation (PCV) with 9 L/min atomized oxygen flow
Study: 30541641
Drug: Simulated scuba
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated scuba test under VCV mode with 9 L/min atomized oxygen flow
Study: 30541641
Drug: Simulated scuba
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated scuba test under PCV mode with 9 L/min atomized oxygen flow
Study: 25551178
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy for impetigo
Study: 16575135
Drug: Inhaled fluticasone
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fluticasone propionate 125 mg twice daily along with macrolides (azitromycin for five days)
Study: 16575135
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated only with antibiotics (macrolides)
Study: 10194656
Drug: Fosinopril (ACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril (ACE inhibitor), 12 weeks treatment
Study: 8946872
Drug: 5‐FU chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU chemotherapy via pelvic retroperitoneal cannulation
Study: 6763175
Drug: Balanced salt
Normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Balanced salt solution or air
Study: 31331575
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (RM and HRV-BF)
Study: 23337728
Drug: Odanacatib 50
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Odanacatib 50 mg weekly
Study: 19835115
Drug: Alternate acupuncture
Normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternate acupuncture group (opposing needling and non-opposing needling, twice daily)
Study: 19835115
Drug: Routine acupuncture
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine acupuncture group (acupuncture at the affected side, once daily)
Study: 11594943
Drug: High-dose antioxidant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose antioxidant formulation (vitamin C, 500 mg; vitamin E, 400 IU; beta carotene, 15 mg)
Study: 9692520
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg orally once a day for 3 days
Study: 3211806
Drug: Combined intramuscular
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intramuscular and oral estrogen treatment (ESTR, n = 41)
Study: 3211806
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (ORX and ESTR)
Study: 23486236
Drug: Probiotic lozenges
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic lozenges containing L. reuteri (DSM 17938 and ATCC PTA 5289; 1 × 10(8) CFU of each strain), 2/day
Study: 23486236
Drug: Placebo lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenges lacking lactobacilli
Study: 18768332
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg qd
Study: 18768332
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg bid
Study: 8186346
Drug: Tripotassium dicitrato
Normalized name: Tripotassium dicitratobismuthate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tripotassium dicitrato bismuthate one tablet q.d.s
Study: 3035166
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral hygiene regimen
Study: 23419093
Drug: Keratinocyte growth
Normalized name: Keratinocyte growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keratinocyte growth factor (palifermin, 60 μg/kg)
Study: 20544030
Drug: Clinician-assisted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinician-assisted treatment
Study: 20544030
Drug: Technician-assisted treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Technician-assisted treatment
Study: 16631431
Drug: 6% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6% carbohydrate solution (n=8)
Study: 16631431
Drug: 6-g essential
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-g essential amino acid mixture (n=8)
Study: 16631431
Drug: Combined carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined carbohydrate and essential amino acid supplement (n=8)
Study: 9553683
Drug: Controfilina-200 (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controfilina-200 (test preparation)
Study: 3189898
Drug: Intrathecal morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal morphine 2.5 mg
Study: 26336919
Drug: Intravenous sodium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sodium bicarbonate (3 ml/kg/h for 1 h; n = 43)
Study: 26336919
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium citrate (75 ml/10 kg divided into 4 doses; n = 43)
Study: 24252587
Drug: Grief-Help (cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grief-Help (cognitive behavioural treatment) combined with five sessions of parental counselling
Study: 18768432
Drug: Depot octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depot octreotide (100 microg subcutaneously on day 1, followed by 20 mg intramuscularly on days 2 and 29)
Study: 17137546
Drug: Antibiotics (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (oral trimethoprim-sulfamethoxazole, amoxicillin, or doxycycline)
Study: 9370552
Drug: ProHance administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProHance administered at doses ranging from 0.1 mmol/kg to 0.3 mmol/kg
Study: 9370552
Drug: ProHance at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProHance at a higher dose level of 0.3 mmol/kg
Study: 1383099
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 micrograms) administered intravenously five minutes before ERCP and subcutaneously 45 minutes after ERCP
Study: 22961907
Drug: Bilberry diet
Normalized name: Bilberry
DrugBank: Bilberry (DB14235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilberry diet (400 g fresh bilberries daily)
Study: 30178742
Drug: Voglibose plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voglibose plus metformin
Study: 30178742
Drug: Individual voglibose
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual voglibose and metformin tablets
Study: 30178742
Drug: Individual voglibose
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual voglibose and metformin tablets and FDC
Study: 8643018
Drug: High-dosed intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dosed intravenous immunoglobulins (0.4 g/kg/daily for five days)
Study: 8643018
Drug: Corticosteroids (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids (500 mg methylprednisolone daily for five days)
Study: 8643018
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with high dose methylprednisolone and immunoglobulins
Study: 8643018
Drug: General medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: General medical care and supportive therapy in the intensive care unit
Study: 7022706
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose carbenicillin prophylaxis preoperatively
Study: 31794130
Drug: Ca+ channel
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca+ channel blocker (verapamil or nicardipine)
Study: 23989522
Drug: 4 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg/day prednisolone (group A, n = 35)
Study: 23989522
Drug: 2 mg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg/day prednisolone (group B, n = 34)
Study: 19996400
Drug: Inhaled oxygen
Normalized name: oxygen Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled oxygen at 100%, 12 L/min, delivered by face mask for 15 minutes.
Study: 2821808
Drug: Alginate/antacid compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alginate/antacid compound (5 g four times a day)
Study: 30668179
Drug: Topical 10%
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10% Potassium hydroxide (KOH) gel applied once daily up to clearing (maximum 30 days)
Study: 30668179
Drug: Topical 10%
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10% Potassium hydroxide (KOH) gel
Study: 27350144
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A injection in the medial orbicularis muscle of the lower eyelid
Study: 26153128
Drug: atrasentan (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: atrasentan (both doses)
Study: 16421658
Drug: Self-administered format
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered format (SA)
Study: 15474212
Drug: Standard drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drug names
Study: 9247610
Drug: Carboplatin administered
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin administered on a single-day schedule
Study: 9247610
Drug: Carboplatin administered
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin administered on a 5-day schedule
Study: 9247610
Drug: Calvert's formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calvert's formula for dosing carboplatin
Study: 8320627
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate 5 mg/kg per day for 6 months
Study: 21081776
Drug: Aprepitant 40
Normalized name: aprepitant 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant 40 mg with dexamethasone 10 mg
Study: 21081776
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg IV with dexamethasone 10 mg
Study: 15525294
Drug: Galantamine 24
Normalized name: galantamine 24 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 24 mg/day for 24 months (total exposure up to 36 months)
Study: 10086898
Drug: L-thyroxine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine supplementation (placebo group)
Study: 7843446
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (hyperprolactinemia) with PRL > 20 ng/mL
Study: 7843446
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (control) with PRL ≤ 20 ng/mL
Study: 836010
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of amoxicillin (250 mg, 500 mg, 1000 mg)
Study: 836010
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of amoxicillin (250 mg, 500 mg, 1000 mg)
Study: 836010
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of amoxicillin (250 mg, 500 mg, 1000 mg)
Study: 836010
Drug: Intramuscular and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular and oral administration of amoxicillin
Study: 836010
Drug: Total absorption
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total absorption of amoxicillin (via urinary recovery and AUC)
Study: 23703915
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment with strengthening exercises
Study: 19411662
Drug: tolvaptan (vasopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolvaptan (vasopressin antagonist)
Study: 17716313
Drug: Subantimicrobial dose
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subantimicrobial dose doxycycline (SDD; 20 mg bid)
Study: 15222726
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation (10 mg generic amlodipine)
Study: 15222726
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (10 mg amlodipine)
Study: 17545892
Drug: Liquid carbohydrate
Normalized name: pyrrolidone carboxylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid carbohydrate (CHO) (200 mL.h, 20% CHO (40 g.h, 160 kcal.h))
Study: 17545892
Drug: Liquid CHO
Normalized name: BOOST LIQUID CHOCOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid CHO (200 mL.h, 20% CHO (40 g.h, 160 kcal.h)) every even hour and solid CHO (25 g of CHO, 10 g of protein, 2 g of fat, and 160 kcal.h) every odd hour
Study: 11488319
Drug: Repeated low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Repeated low-dose allergen exposure
Study: 9791040
Drug: Neutral endopeptidase
Normalized name: Neutral endopeptidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral endopeptidase inhibitor (SCH 32615, 200 mg intravenously)
Study: 29949479
Drug: 40-minute application
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-minute application of 38% hydrogen peroxide bleaching agent
Study: 29949479
Drug: Two 20-minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 20-minute applications of 38% hydrogen peroxide bleaching agent
Study: 24439637
Drug: High frequency
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High frequency TENS treatment
Study: 19712802
Drug: Testosterone (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone (intramuscular injection every 6 weeks)
Study: 15223252
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (i.v.IG)
Study: 11259862
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg for two days)
Study: 9482562
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of terfenadine and pseudoephedrine
Study: 8046193
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (physician-targeted treatment recommendations)
Study: 3242386
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg x 3)
Study: 3242386
Drug: Estramustine (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estramustine (280 mg x 2)
Study: 27918744
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg + Esomeprazole 20 mg (NE)
Study: 26353772
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with S-1/irinotecan/bevacizumab (SIRB or IRIS/bevacizumab)
Study: 21219394
Drug: Water-cooled Nd:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-cooled Nd:YAG laser (1064 nm, 6 W, 400 mJ) adjunctive to supra- and subgingival debridement (SRP)
Study: 9063317
Drug: Benzathine penicillin
Normalized name: Benzathine penicillin G
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin G (single-dose)
Study: 8224684
Drug: Rectal endoscopic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal endoscopic ultrasonography
Study: 23998557
Drug: Propionyl-L-carnitine (PLC)
Normalized name: glycine propionyl-L-carnitine
DrugBank: Levocarnitine propionate (DB15980)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (PLC) 2g/day orally for 4 months